You are here:    Home For Scientists Drug Discovery Initiative NF Preclinical Consortium

ja_mageia

DDI NF Preclinical Consortium PDF Print E-mail

The NF Preclinical Consortium is a multi-site collaboration of six research
Centers, each focused on different tumor manifestations of NF1 and NF2.
The Centers of the Consortium began working together in 2008,and
are now collaborating to test candidate NF drug therapies in parallel in
multiple NF tumors models.It is anticipated that this approach will yield
maximum information in a short time on a drugs potentialfor treating
an array of NF tumors.

Centers 
University of California, San Francisco
Director: Kevin Shannon, MD, Ph.D.
Deputy Director: Jennifer Lauchle, M.D.
Tumor Focus:  NF1 myeloid leukemia

Washington University School of Medicine
Director: David Gutmann, MD, Ph.D.
Deputy Director: Joshua Rubin, MD, Ph.D.
Tumor Focus:  NF1 optic pathway glioma          

Cincinnati Children’s Hospital Medical Center
Director: Timothy Cripe, MD, Ph.D.
 Deputy Director: Nancy Ratner, Ph.D.
Tumor Focus: NF1 plexiform tumors & dermal neurofibromas

House Ear Institute
Director: Marco Giovannini, MD, Ph.D.
Deputy Directors: Fabrice Chareyre, Ph.D.;Oliver Hanneman, MD, Ph.D.;
Michel Kalamarides, Ph.D.
Tumor Focus: NF2 schwannoma, meningioma
                                                                                                                                                                                                                           
Harvard Med School/Mass General Hospital
Director: Andrea McClatchey, Ph.D.
Deputy Director: Ichiko Saotome, Ph.D.
Tumor Focus: NF2 schwannoma, meningioma   

Harvard Medical School/Brigham & Women’s Hospital
Director: Karen Cichowski, Ph.D.                   
Deputy Directors: Thomas De Raedt, Ph.D. & Ophelia Maertens, Ph.D.
Tumor Focus: NF1 malignant peripheral nerve sheath tumors     

Oversight Committee
 
Jay Gibbs, Ph.D. (Chair), AstraZeneca Pharmaceuticals

Gideon E. Bollag, Ph.D., Plexxikon Inc.

Sara A. Courtneidge, Ph.D. , The Burnham Inst. for Medical Research

Larry Gelbert, Ph.D., Eli Lilly and Company 

Filippo G. Giancotti, M.D., Ph.D. Memorial Sloan-Kettering Cancer Center

Janet M Hock, BDS, Ph.D., Maine Institute for Human Genetics and Health

Christopher L. Moertel, MD, Children's Hospitals and Clinics of Minnesota

Michael J. Morin, Ph.D., Oncovia, Inc.

Roger J. Packer, MD, Children’s National Medical Center 

Frank McCormick, Ph.D., University of California, San Francisco

Edward Stern, Esq.,  Legal Counel to the CTF Medical Advisory Committee


Questions? Contact:
Kim Hunter-Schaedle, Ph.D.
Chief Scientific Officer
Children's Tumor Foundation
95 Pine Street, 16th Floor
New York, NY 10005
Tel: 212-344-6633 x 231
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it